Travacom Post Marketing Surveillance Study

Exclusion Criteria

• •Women of childbearing potential (not postmenopausal for at least one year or not surgically sterile) who are currently pregnant, have a positive result on the urine pregnancy test at Screening, intend to become pregnant during the study period, are breastfeeding, or do not agree to use an adequate birth control method to prevent pregnancy throughout the study.
• •Chronic, recurrent, or severe inflammatory eye disease, such as scleritis, uveitis, or herpes keratitis.
• •History of clinically significant or progressive retinal disease.
• •Best corrected visual acuity (BCVA) score worse than 20/80 Snellen.
• •Bronchial asthma or related history that would preclude safe administration of a topical beta-blocker.
• •Severe, unstable, or uncontrolled cardiovascular, hepatic, or renal disease or related history that would preclude safe administration of a topical beta-adrenergic blocking agent.
• •History of spontaneous or current hypoglycemia or uncontrolled diabetes.
• •Known medical allergy, hypersensitivity, or poor tolerance to any component of Travacom deemed clinically significant in the opinion of the Principal Investigator.
• •Use of any additional topical or system ocular hypotensive medication during the study.
• •Participation in any other investigational study within 30 days prior to Screening visit.